{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:15:55Z","timestamp":1790961355542,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"DOI":"10.7759\/cureus.50159","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T11:43:12Z","timestamp":1702035792000},"source":"Crossref","is-referenced-by-count":11,"title":["A Comprehensive Review on Non-Alcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Prerna","family":"Sahu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyaksh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok M","family":"Mehendale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice J","year":"2018","unstructured":"Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med. 2018, 18:245-50. 10.7861\/clinmedicine.18-3-245","journal-title":"Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0806-8","article-title":"Non-alcoholic fatty liver disease","volume":"15","author":"Neuschwander-Tetri BA","year":"2017","unstructured":"Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017, 15:45. 10.1186\/s12916-017-0806-8","journal-title":"BMC Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo X","year":"2022","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022, 23:15489. 10.3390\/ijms232415489","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S32-42. 10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell EE","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021, 397:2212-24. 10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24726","article-title":"Ethnicity and nonalcoholic fatty liver disease","volume":"55","author":"Bambha K","year":"2012","unstructured":"Bambha K, Belt P, Abraham M, et al.. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012, 55:769-80. 10.1002\/hep.24726","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311854","article-title":"Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study","volume":"66","author":"Sinn DH","year":"2017","unstructured":"Sinn DH, Kang D, Chang Y, et al.. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017, 66:323-9. 10.1136\/gutjnl-2016-311854","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki A","year":"2013","unstructured":"Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013, 14:20704-28. 10.3390\/ijms141020704","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13622","article-title":"Mitochondria, oxidative stress and nonalcoholic fatty liver disease: a complex relationship","volume":"52","author":"Karkucinska-Wieckowska A","year":"2022","unstructured":"Karkucinska-Wieckowska A, Simoes IC, Kalinowski P, et al.. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: a complex relationship. Eur J Clin Invest. 2022, 52:e13622. 10.1111\/eci.13622","journal-title":"Eur J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir F","year":"2022","unstructured":"Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules. 2022, 12:824. 10.3390\/biom12060824","journal-title":"Biomolecules"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-9-42","article-title":"The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"9","author":"Liu Q","year":"2010","unstructured":"Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010, 9:42. 10.1186\/1476-511X-9-42","journal-title":"Lipids Health Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase DM","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, et al.. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020, 2020:3920196. 10.1155\/2020\/3920196","journal-title":"J Diabetes Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i8.1166","article-title":"Fructose as a key player in the development of fatty liver disease","volume":"19","author":"Basaranoglu M","year":"2013","unstructured":"Basaranoglu M, Basaranoglu G, Sabuncu T, Sent\u00fcrk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol. 2013, 19:1166-72. 10.3748\/wjg.v19.i8.1166","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen Z","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020, 152:116-41. 10.1016\/j.freeradbiomed.2020.02.025","journal-title":"Free Radic Biol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.281.5.G1135","article-title":"Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress","volume":"281","author":"Robertson G","year":"2001","unstructured":"Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001, 281:G1135-9. 10.1152\/ajpgi.2001.281.5.G1135","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00426.2001","article-title":"Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis","volume":"282","author":"Pessayre D","year":"2002","unstructured":"Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2002, 282:G193-9. 10.1152\/ajpgi.00426.2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283395e5c","article-title":"Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis","volume":"21","author":"Flamment M","year":"2010","unstructured":"Flamment M, Kammoun HL, Hainault I, Ferr\u00e9 P, Foufelle F. Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis. Curr Opin Lipidol. 2010, 21:239-46. 10.1097\/MOL.0b013e3283395e5c","journal-title":"Curr Opin Lipidol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2010.3790","article-title":"Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease","volume":"15","author":"Gentile CL","year":"2011","unstructured":"Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal. 2011, 15:505-21. 10.1089\/ars.2010.3790","journal-title":"Antioxid Redox Signal"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3976","article-title":"Targeting the unfolded protein response in disease","volume":"12","author":"Hetz C","year":"2013","unstructured":"Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov. 2013, 12:703-19. 10.1038\/nrd3976","journal-title":"Nat Rev Drug Discov"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-48382-5_8","article-title":"What is lipotoxicity?","author":"Engin AB","year":"2017","unstructured":"Engin AB. What is lipotoxicity?. Obesity and lipotoxicity.  Engin A (ed): Springer, Cham; 2017. 197-220. 10.1007\/978-3-319-48382-5_8"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095146","article-title":"Lipotoxicity as the leading cause of non-alcoholic steatohepatitis","volume":"23","author":"Brankovi\u0107 M","year":"2022","unstructured":"Brankovi\u0107 M, Jovanovi\u0107 I, Duki\u0107 M, Radonji\u0107 T, Opri\u0107 S, Kla\u0161nja S, Zdravkovi\u0107 M. Lipotoxicity as the leading cause of non-alcoholic steatohepatitis. Int J Mol Sci. 2022, 23:5146. 10.3390\/ijms23095146","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2019.05.029","article-title":"Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease","volume":"144","author":"Svegliati-Baroni G","year":"2019","unstructured":"Svegliati-Baroni G, Pierantonelli I, Torquato P, et al.. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic Biol Med. 2019, 144:293-309. 10.1016\/j.freeradbiomed.2019.05.029","journal-title":"Free Radic Biol Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05733.x","article-title":"Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes","volume":"24","author":"Ricchi M","year":"2009","unstructured":"Ricchi M, Odoardi MR, Carulli L, et al.. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol. 2009, 24:830-40. 10.1111\/j.1440-1746.2008.05733.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso G","year":"2018","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology. 2018, 155:282-302.e8. 10.1053\/j.gastro.2018.06.031","journal-title":"Gastroenterology"},{"key":"ref26","article-title":"Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations","volume":"11","author":"Younossi ZM","year":"1998","unstructured":"Younossi ZM, Gramlich T, Liu YC, et al.. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998, 11:560-5.","journal-title":"Mod Pathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad P","year":"2003","unstructured":"Mofrad P, Contos MJ, Haque M, et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003, 37:1286-92. 10.1053\/jhep.2003.50229","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1091983","article-title":"Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive","volume":"28","author":"Wieckowska A","year":"2008","unstructured":"Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008, 28:386-95. 10.1055\/s-0028-1091983","journal-title":"Semin Liver Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu V","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005, 128:1898-906. 10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina E","year":"2017","unstructured":"Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017, 49:197-211. 10.1080\/03602532.2017.1293683","journal-title":"Drug Metab Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni C","year":"1999","unstructured":"Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, Mccullough A. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999, 116:1413-9. 10.1016\/S0016-5085(99)70506-8","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","author":"Angulo P","year":"1999","unstructured":"Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999, 30:1356-62. 10.1002\/hep.510300604","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt EM","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999, 94:2467-74. 10.1111\/j.1572-0241.1999.01377.x","journal-title":"Am J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner DE","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41:1313-21. 10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa P","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, et al.. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012, 56:1751-9. 10.1002\/hep.25889","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1111\/j.1572-0241.2003.07659.x","article-title":"The natural history of nonalcoholic fatty liver disease: a clinical histopathological study","volume":"98","author":"Harrison SA","year":"2003","unstructured":"Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003, 98:2042-7.","journal-title":"Am J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016, 64:1388-402. 10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon TG","year":"2021","unstructured":"Simon TG, Roelstraete B, Sharma R, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology. 2021, 74:2410-23. 10.1002\/hep.31845","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m H","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017, 67:1265-73. 10.1016\/j.jhep.2017.07.027","journal-title":"J Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro R","year":"2022","unstructured":"Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med. 2022, 292:190-204. 10.1111\/joim.13531","journal-title":"J Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo M","year":"2010","unstructured":"Lazo M, Solga SF, Horska A, et al.. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010, 33:2156-63. 10.2337\/dc10-0856","journal-title":"Diabetes Care"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.38","article-title":"Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: results of a pilot randomized open clinical trial","volume":"7","author":"Mac\u00edas-Rodr\u00edguez RU","year":"2016","unstructured":"Mac\u00edas-Rodr\u00edguez RU, Ilarraza-Lomel\u00ed H, Ruiz-Marg\u00e1in A, et al.. Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: results of a pilot randomized open clinical trial. Clin Transl Gastroenterol. 2016, 7:e180. 10.1038\/ctg.2016.38","journal-title":"Clin Transl Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner M","year":"2022","unstructured":"Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2022, 71:194-209. 10.1136\/gutjnl-2021-324305","journal-title":"Gut"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola R","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, et al.. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023, 24:1703. 10.3390\/ijms24021703","journal-title":"Int J Mol Sci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245721","article-title":"Non-alcoholic fatty liver disease (NAFLD) and bariatric\/metabolic surgery as its treatment option: a review","volume":"10","author":"G\u0142uszy\u0144ska P","year":"2021","unstructured":"G\u0142uszy\u0144ska P, Lemancewicz D, Dzi\u0119cio\u0142 JB, Razak Hady H. Non-alcoholic fatty liver disease (NAFLD) and bariatric\/metabolic surgery as its treatment option: a review. J Clin Med. 2021, 10:5721. 10.3390\/jcm10245721","journal-title":"J Clin Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects","volume":"11","author":"Laursen TL","year":"2019","unstructured":"Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Gr\u00f8nb\u00e6k H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019, 11:138-49. 10.4254\/wjh.v11.i2.138","journal-title":"World J Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010360","article-title":"Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 mice model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 pathway","volume":"21","author":"Chyau CC","year":"2020","unstructured":"Chyau CC, Wang HF, Zhang WJ, Chen CC, Huang SH, Chang CC, Peng RY. Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 mice model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 pathway. Int J Mol Sci. 2020, 21:360. 10.3390\/ijms21010360","journal-title":"Int J Mol Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1039\/d0fo02736g","article-title":"Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD","volume":"12","author":"Li J","year":"2021","unstructured":"Li J, Wang T, Liu P, Yang F, Wang X, Zheng W, Sun W. Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD. Food Funct. 2021, 12:3898-918. 10.1039\/d0fo02736g","journal-title":"Food Funct"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2013.11.016","article-title":"Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation","volume":"30","author":"Andrade JM","year":"2014","unstructured":"Andrade JM, Para\u00edso AF, de Oliveira MV, et al.. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014, 30:915-9. 10.1016\/j.nut.2013.11.016","journal-title":"Nutrition"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.02.006","article-title":"Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway","volume":"9","author":"Liu Y","year":"2019","unstructured":"Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019, 9:745-57. 10.1016\/j.apsb.2019.02.006","journal-title":"Acta Pharm Sin B"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida Y","year":"2018","unstructured":"Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol. 2018, 53:362-76. 10.1007\/s00535-017-1415-1","journal-title":"J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/209880-a-comprehensive-review-on-non-alcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:01Z","timestamp":1707509341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/209880-a-comprehensive-review-on-non-alcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.50159","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}